Inhaled PRS-220 May Be Better Than Into-the-vein Pamrevlumab for IPF

Inhaled PRS-220 May Be Better Than Into-the-vein Pamrevlumab for IPF

305275

Inhaled PRS-220 May Be Better Than Into-the-vein Pamrevlumab for IPF

In preclinical studies, PRS-220, Pieris Pharmaceuticals’ experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), showed stronger lung tissue penetration and anti-scarring effects than pamrevlumab — an into-the-vein, mechanistically similar IPF therapy currently being tested in a Phase 3 clinical trial. These promising findings, which support Pieris’ plans to launch a Phase 1 trial of PRS-220 next year, were presented in a poster titled, “Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of…

You must be logged in to read/download the full post.